Document:

QuickLinks
 -- Click here to rapidly navigate through this document
  

 
 

Exhibit 10.13    
    

***Text Omitted and Filed Separately

Pursuant to a Confidential Treatment Request

Under C.F.R. §§ 200.80(b)(4) and Rule 406

of the Securities Act of 1933, as amended.  

 SUPPLEMENT  

This
Supplement made and entered into by and between Kyowa Hakko Kogyo Co., Ltd., a Japanese corporation having its principal offices at 1-6-1 Ohtemachi,
Chiyoda-ku, Tokyo, 100-8185, Japan (hereinafter referred to as "KH") and NovaCardia, Inc., a Delaware corporation having its principal offices at 12230 El Camino Real,
Suite 300, San Diego, California 92130, the United States of America (hereinafter referred to as "NC"). 

WITNESSETH  

WHEREAS,
KH and NC have entered into a License Agreement dated August 14, 2003 (hereinafter referred to as "License Agreement') and wish to supplement the License Agreement as set forth herein; 

NOW,
THEREFORE, the parties agree as follows: 

ARTICLE 1 LICENSE AGREEMENT  

	1.1
	This Supplement shall be deemed to be integral part of the License Agreement.

	1.2
	In the case that a certain term used in this Supplement is defined in the License Agreement, such term has the same meaning as such
definition. 

ARTICLE 2 DEFINITIONS  

	2.1
	The term "NC Specific Patent" shall mean the US patent application numbers
[. . .***. . .] and the US provisional patent application number
[. . .***. . .], the US patents derived from such US patent applications and US provisional patent application, the
non-US counterpart patent applications which are filed by NC and claim priority to or common priority with such US patent applications or US provisional patent application, and the
non-US patents derived from such non-US counterpart patent applications.

	2.2
	The term "NC Other Patent" shall mean the patent applications which are filed by NC and claim the inventions specifically related to
the KW-3902 or the Product, and the patents derived from such patent applications. The NC Other Patent shall include neither the NC Specific Patent nor the patents and patent applications
related to the manufacture of the KW-3902 or the product.

	2.3
	The NC Patent shall collectively mean the NC Specific Patent and the NC Other Patent.

	2.4
	The term "KH Patent" shall mean the patent applications which are filed by KH after the Effective Date and claim the inventions
specifically related to the KW-3902 or the Product, and the patents derived from such patent applications. The KH Patent shall not include the patents and patent applications related to
the manufacture of the KW-3902 or the Product 
***Confidential Treatment Requested

1

 

ARTICLE 3 PATENT PROSECUTION  

	3.1
	As soon as practicable after NC has filed the NC Other Patent, NC shall notify KH in writing of such NC Other Patent. In any country of
KH's choice in the KH Territory, NC shall, at KH's cost, file, prosecute and maintain the NC Patent of KH's choice if such filing is legally permissible and is requested in writing by KH at latest
[. . .***. . .]. Such country shall be hereinafter referred to as "KH Country". NC shall make reasonable efforts to file, to
prosecute and to maintain such NC Patent in the KH Country and shall timely provide KH with the main documentation relating to such filing, prosecution and maintenance so that KH may support such
filing, prosecution and maintenance.

	3.2
	KH may, at one (1) month written notice to NC, relinquish its request for such filing, prosecution and maintenance as provided
for in Article 3.1. Such notice shall specify after which date, in which KH Country and for which NC Patent KH does not request such filing, prosecution and maintenance. After such date, NC
shall not be obligated to file, to prosecute and to maintain such NC Patent in such KH Country. KH shall not be obligated to pay the costs and expenses which NC incurs to file, to prosecute and to
maintain such NC Patent in such KH Country after such date.

	3.3
	KH shall pay to NC the costs and expenses, which are payable to NC by KH under Articles 3.1 and 3.2, within forty-five
(45) days within KH's receipt of NC's invoice therefor.

	3.4
	As soon as practicable after KH has filed the KH Patent, KH shall notify NC in writing of such KH Patent. In any country of NC's choice
in the NC Territory, KH shall, at NC's cost, file, prosecute and maintain the KH Patent of NC's choice if such filing is legally permissible and is requested in writing by NC at latest
[. . .***. . .]. Such country shall be hereinafter referred to as "NC Country". KH shall make reasonable efforts to file, to
prosecute and to maintain such KH Patent in the NC Country and shall timely provide NC with the main documentation relating to such filing, prosecution and maintenance so that NC may support such
filing, prosecution and maintenance.

	3.5
	NC may, at one (1) month written notice to KH, relinquish its request for such filing, prosecution and maintenance as provided
for in Article 3.4. Such notice shall specify after which date, in which NC Country and for which KH Patent NC does not request such filing, prosecution and maintenance. After such date, KH
shall not be obligated to file, to prosecute and to maintain such KH Patent in such NC Country. NC shall not be obligated to pay the costs and expenses which KH incurs to file, to prosecute and to
maintain such KH Patent in such NC Country after such date.

	3.6
	NC shall pay to KH the costs and expenses, which are payable to KH by NC under Articles 3.4 and 3.5, within forty-five
(45) days within NC's receipt of KH's invoice therefor. 
***Confidential Treatment Requested

2

 

ARTICLE 4 PATENT LICENSE  

	4.1
	NC shall grant to KH a non-exclusive and paid-up license (with the right to grant a sublicense), only as
relates to the KW-3902, to practice the NC Patent of KH's choice in the KH Country within the Field unless NC, in its reasonable discretion, determines that such license would be
disadvantageous to NC and so notifies KH in writing of the grounds for such determination within sixty (60) days after KH notifies NC in writing of such choice. When the NC Patent is not part
of the public domain, KH may, only with NC's prior written consent, disclose such NC Patent to an entity for such sublicense under appropriate confidentiality and shall be responsible for the
confidentiality and limited-usage with which the entity is obligated to comply as such sublicensee.

	4.2
	KH shall grant to NC a non-exclusive and paid-up license (with the right to grant a sublicense), only as
relates to the KW-3902, to practice the KH Patent of NC's choice in the NC Country within the Field unless KH, in its reasonable discretion, determines that such license would be
disadvantageous to KH and so notifies NC in writing of the grounds for such determination within sixty (60) days after NC notifies KH in writing of such choice. When the KH Patent is not part
of the public domain, NC may, only with KH's prior written consent, disclose such KH Patent to an entity for such sublicense under appropriate confidentiality and shall be responsible for the
confidentiality and limited-usage with which the entity is obligated to comply as such sublicensee. 

ARTICLE 5 CONFIDENTIALITY  

	5.1
	The NC Patent shall be deemed to be part of NC's Confidential Information unless it is part of the public domain.

	5.2
	The KH Patent shall be deemed to be part of KH's Confidential Information unless it is part of the public domain. 

ARTICLE 6 TERM AND TERMINATION  

	6.1
	This Supplement shall come into effect as of the last date when each party signs this Supplement.

	6.2
	When the License Agreement expires (as not earlier terminated according thereto) as provided for in Section 26.1 thereof
Articles 3, 4 and 5, and this Article 6.2 shall survive such expiration.

	6.3
	When the License Agreement is terminated by NC according to Section 26.2 thereof or by KH according to Section 19.3 or
26.3 thereof, Articles 3.1, 3.2, 3.3, 4.1 and 5, and this Article 6.3 shall survive such termination.

	6.4
	When the License Agreement is terminated by NC according to Section 19.3 or 26.3 thereof, Articles 3.4, 3.5, 3.6, 4.2 a d 5 and
this Article 6.4 shall survive such termination. 

3

 

        IN
WITNESS WHEREOF, the parties have caused this Supplement to be executed by their duly authorized representatives. 

	KYOWA HAKKO KGOYO CO,, LTD.	 	NOVACARDIA, INC.
	
By:	
 	

/s/ Yoshito Imai
	
 	

By:	
 	

/s/ Randall Woods

	Name:	 	Yoshito Imai	 	Name:	 	Randall Woods
	Title:	 	Senior Managing Director	 	Title:	 	Chief Executive Officer
	

Date:	
 	

March 23, 2005	
 	

Date:	
 	

March 30, 2005

4

QuickLinks

Exhibit 10.13QuickLinks
 -- Click here to rapidly navigate through this document
  

 
 

Exhibit 10.14    
    

***Text Omitted and Filed Separately

Pursuant to a Confidential Treatment Request

Under C.F.R. §§ 200.80(b)(4) and Rule 406

of the Securities Act of 1933, as amended.  

 SETTLEMENT AGREEMENT  

        THIS SETTLEMENT AGREEMENT (this "Settlement Agreement") is entered
into on this 31st day of March 2005 by and between NOVACARDIA, INC. ("NC"),
a Delaware corporation and KYOWA HAKKO KOGYO CO., LTD. ("KH"), a Japanese corporation. 

        WHEREAS, NC and KH executed a license agreement dated August 14, 2003 (the "License
Agreement") whereby KH granted to NC a license under certain patent and know-how rights relating to "KW-3902" (as defined in the License Agreement); 

        WHEREAS, KH inadvertently allowed [. . .***. . .] Patent No.
[. . .***. . .], covered by the License Agreement, to expire; 

        WHEREAS, NC is willing to settle with KH and release KH from any claims by NC relating to the inadvertent abandonment by KH of
[. . .***. . .] Patent No. [. . .***. . .] in
consideration of the terms set forth in this Settlement Agreement; 

        NOW THEREFORE, the parties agree as follows (all capitalized terms unless otherwise defined herein having the same meaning as defined in
the License Agreement): 

1.    Non-Negotiation Period Payment Date Deferral    

        CURRENT PROVISIONS:    Under Section 3.5 of the License Agreement, if NC were to extend the Non-Negotiation
Period for [. . .***. . .], NC would have been required to pay to KH the amount of
[. . .***. . .] Dollars (US$[. . .***. . .]) by
[. . .***. . .]. 

        AS AMENDED PER THIS SETTLEMENT AGREEMENT:    If NC desires to extend the Non-Negotiation Period beyond
[. . .***. . .], NC must give written notice to KH of NC's intention by
[. . .***. . .], thereby immediately giving rise to an accrual of an obligation by NC to pay
[. . .***. . .] Dollars (US$[. . .***. . .]) to
KH, but the actual remittance date for such payment shall be deferred to [. . .***. . .]. For avoidance of doubt, once NC
has given notice to KH of NC's intention to extend the Non-Negotiation Period, the [. . .***. . .] Dollar
(US$[. . .***. . .]) payment shall be due on
[. . .***. . .] regardless of whether or not NC later decides to pursue or not to pursue an actual license under
Section 3.5 of the License Agreement. 

2.    Revised List of Licensed Patents: Exhibit 2    

        Attached
hereto is a revised Exhibit 2 which hereby replaces in its entirety the existing Exhibit 2 of the License Agreement. 

3.    Release of Any Claims by NC Based Upon  [. . .***. . .] Patent
[. . .***. . .]    

        NC
agrees that this Settlement Agreement is in full satisfaction of any claims or rights to compensation that NC might otherwise have arising from KH's failure to maintain
[. . .***. . .] Patent [. . .***. . .]. NC
accordingly hereby releases KH from any past or future, known or unknown claim arising under or related to the matter of
[. . .***. . .] Patent [. . .***. . .]. This 

***Confidential Treatment Requested

1

 

release
shall be effective regardless of whether or not NC chooses to extent the Non-Negotiation Period beyond
[. . .***. . .]. 

4.    No Other Change    

        Except
as provided in this Settlement Agreement, all other provisions of the License Agreement remain unchanged and in full force and effect. The governing law and arbitration provisions
of Sections 27 and 28 of the License Agreement shall apply to this Settlement Agreement. 

        IN WITNESS WHEREOF, the parties have caused this Settlement Agreement to be executed by their duly authorized representatives. 

	NOVA CARDIA INC.	 	KYOWA HAKKO KOGYO CO., LTD.
	
 /s/ Randall Woods
	
 	

/s/ Yoshito Imai

	Name:	 	Randall Woods	 	Name:	 	Yoshito Imai
	

Title:	
 	

Chief Executive Officer	
 	

Title:	
 	

Senior Managing Director
	

Date:	
 	

5/17/2005	
 	

Date:	
 	

5/11/2005

***Confidential Treatment Requested

2

EXHIBIT 2 (THE PATENT)  

	Part A [. . .***. . .]	 	 	 	 
	

[. . .***. . .]	
 	

Application Number: [. . .***. . .]	
 	

Application Date: [. . .***. . .]
	 	 	Registration Number: [. . .***. . .]	 	Registration Date: [. . .***. . .]
	 	 	Expiration Date: [. . .***. . .]	 	Status: [. . .***. . .]
	

Part B: [. . .***. . .]	
 	

 	
 	

 
	

[. . .***. . .]	
 	

Application Number: [. . .***. . .]	
 	

Application Date: [. . .***. . .]
	 	 	Registration Number: [. . .***. . .]	 	Registration Date: [. . .***. . .]
	 	 	Expiration Date: [. . .***. . .]	 	Status: [. . .***. . .]
	

Part C: [. . .***. . .]	
 	

 	
 	

 
	

[. . .***. . .]	
 	

Application Number: [. . .***. . .]	
 	

Application Date: [. . .***. . .]
	 	 	Registration Number: [. . .***. . .]	 	Registration Date: [. . .***. . .]
	 	 	Expiration Date: [. . .***. . .]	 	Status: [. . .***. . .]

***Confidential Treatment Requested

QuickLinks

Exhibit 10.14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}]]